Antiendotoxin strategies

Infectious Disease Clinics of North America

Volumn 13, Issue 2, 1999, Pages 371-386

  Hellman, J ^a   Warren, H S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; ENDOTOXIN ANTIBODY; LIPID A; LIPOPOLYSACCHARIDE; POLYMYXIN B;

ANTIBACTERIAL ACTIVITY; GRAM NEGATIVE BACTERIUM; IMMUNIZATION; INFLAMMATION; PLASMAPHERESIS; PROTEIN BINDING; REVIEW; SEPSIS;

EID: 0033061956     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70080-5     Document Type: Article

References (158)

1. Abrahamson S.L. Wu H.-M. R.E. Williams Biochemical characterization of recombinant fusions of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein J Biol Chem 272 1997 2149
2. B. Agerberth H. Gunne J. Odeberg FALL-39, a putative human peptide antibiotic, is cystein-free and expressed in bone marrow and testis Proc Natl Acad Sci U S A 92 1995 195
3. Y. Aida K. Kusumoto K. Nakatomi An analogue of lipid A and LPS from Rhodobacter sphaeroides inhibits neutrophil responses to LPS by blocking receptor recognition of LPS and by depleting LPS-binding protein in plasma J Leukoc Biol 58 1995 675
4. G.A. Alpert G. Baldwin C. Thompson Limulus antilipopolysaccharide factor protects rabbits from meningococcocal endotoxin shock J Infect Dis 165 1992 494
5. W.S. Ammons A.H.C. Kung Recombinant amino terminal fragment of bactericidal/permeability-increasing protein prevents hemodynamic responses to endotoxin Circulatory Shock 41 1993 176
6. H. Aoki M. Kodama T. Tani Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber Am J Surg 167 1994 412
7. M.E. Astiz E.C. Rackow J.G. Still Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: A prospective, double-blind, randomized, controlled trial Crit Care Med 23 1995 9
8. M.E. Astiz D.C. Saha K. Brooks Comparison of the induction of endotoxin tolerance in endotoxemia and peritonitis by monophosphoryl lipid A and lipopolysaccharide Circulatory Shock 39 1993 194
9. R.J. Bauer M.L. White N. Wedel A phase I safety and pharmacokinetic study of a recombinant amino terminal fragment of bactericidal/permeability-increasing protein in healthy male volunteers Shock 5 1996 91
10. L.J. Beamer S.F. Carroll D. Eisenberg Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution Science 276 1997 1861
11. S. Bende L. Bertok Elimination of endotoxin from the blood by extracorporeal activated charcoal hemoperfusion in experimental canine endotoxin shock Circultory Shock 19 1986 239
12. N.M. Bhat M.M. Bieber C.J. Chapman Human anti-lipid A monoclonal antibodies bind to human B cells and the i antigen on cord red blood cells J Immunol 151 1993 5011
13. A.K. Bhattacharjee S.M. Opal J.E. Palardy Affinity-purified Escherichia coli J5 lipopolysaccharide-specific IgG protects neutropenic rats against gram-negative bacterial sepsis J Infect Dis 170 1994 622
14. A.K. Bhattacharjee S.M. Opal R. Taylor A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis group B outer membrane protein produces protective antibodies against gram-negative bacteremia J Infect Dis 173 1996 1157
15. T.P. Birkland R.D. Cornwell D.T. Golenbock Comparative study of lipopolysaccharide-, lipid IVa-, and lipid X-induced tumor necrosis factor production in murine macrophage-like cell lines N Engl J Med 256 1990 399
16. R.C. Bone R.A. Balk A.M. Fein A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial Crit Care Med 23 1995 994
17. A.I. Braude H. Douglas C.E. Davis Treatment and prevention of intravascular coagulation with antiserum to endotoxin J Infect Dis 128 1973 S157
18. S.E. Bucklin P. Lake L. Logdberg Therapeutic efficacy of a polymyxin B-dextran 70 conjugate in experimental model of endotoxemia Antimicrob Agents Chemother 39 1995 1462
19. G.K. Bysani J.L. Shenep W.K. Hildner Detoxification of plasma containing lipopolysaccharide by adsorption Crit Care Med 18 1990 67
20. C.M. Carpati M.E. Astiz E.C. Rackow Monophosphoryl lipid A attenuates the effect of endotoxic shock in pigs J Lab Clin Med 119 1992 346
21. Cavaillon J.-M. C. Fitting N. Haeffner-Cavaillon Cytokine response by monocytes and macrophages to free and lipoprotein-bound lipopolysaccharide Infect Immun 58 1990 2325
22. W.G. Cheadle K. Hanasawa R.N. Gallinaro Endotoxin filtration and immune stimulation improve survival from gram-negative sepsis Surgery 110 1991 785
23. L. Chedid M. Parant F. Boyer A proposed mechanism for natural immunity to enterobacterial pathogens J Immunol 100 1968 292
24. W.J. Christ O. Asano A.L.C. Robidoux E5531, a pure endotoxin antagonist of high potency Science 268 1995 80
25. S.B. Corradin D. Heumann P. Gallay Bactericidal/permeability-increasing protein inhibits induction of macrophage nitric oxide production by lipopolysaccharide J Infect Dis 169 1994 105
26. Corrigan J.J. Jr B.M. Bell Endotoxin-induced intravascular coagulation: Prevention with polymyxin B sulphate J Lab Clin Med 77 1971 802
27. J.B. Cowland A.H. Johnsen N. Borregaard hCAP-18, a cathelin/pro-bactenecin-like protein of human neutrophil specific granules FEBS Lett 368 1995 173
28. A.S. Cross Antiendotoxin antibodies: A dead end? Ann Intern Med 121 1994 58
29. R.L. Danner K.A. Joiner M. Rubin Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide Antimicrob Agents Chemother 33 1989 1428
30. Dentener M.A. Von Asmuth E.J.U. G.J.M. Francot Antagonistic effects of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein on lipopolysaccharide-induced cytokine release by mononuclear phagocytes: Competition for binding to lipopolysaccharide J Immunol 151 1993 4258
31. Di Padova F. H. Brade G.R. Barclay A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides Infect Immun 61 1993 3863
32. G.S. Doig C.M. Martin W.J. Sibbald Polymyxin-dextran antiendotoxin pretreatment in an ovine model of normotensive sepsis Crit Care Med 25 1997 1956
33. J. Drabick A. Bhattacharjee W. Williams Covalent polymyxin B-starch and polymyxin B-immunoglobulin G conjugates as novel anti-endotoxin agents [abstract] Clinical Research 40 1992 287A
34. J.J. Drabick A.K. Bhattacharjee D.L. Hoover Covalent polymyxin B conjugate with human immunoglobulin G as an antiendotoxin reagent Antimicrob Agents Chemother 42 1998 583
35. P. Elsbach J. Weiss The bactericidal/permeability-increasing protein (BPI), a potent element in host-defense against gram-negative bacteria and lipopolysaccharide Immunobiology 187 1993 417
36. P. Elsbach J. Weiss Bactericidal/permeability increasing protein and host defense against gram-negative bacteria and endotoxin Curr Opin Immunol 5 1993 103
37. K. Emancipator G. Csako R.J. Elin In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins Infect Immun 60 1992 596
38. K.R. Feingold J.L. Funk A.H. Moser Role for circulating lipoproteins in protection from endotoxin toxicity Infect Immun 63 1995 2041
39. Fisher C.J. Jr M.N. Marra J.E. Palardy Human neutrophil bactericidal/permeability-increasing protein reduces mortality rate from endotoxin challenge: A placebo-controlled study Crit Care Med 22 1994 553
40. W.A. Flegel M.W. Baumstark C. Weinstock Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I Infect Immun 61 1993 5140
41. W.A. Flegel A. Wolpl D.N. Mannel Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins Infect Immun 57 1989 2237
42. M.A. Fletcher M. Kloczewiak P.M. Loiselle TALF peptide-immunoglobulin conjugates that bind lipopolysaccharide Journal of Endotoxin Research 3 1996 49
43. 106–138-IgG that binds and neutralizes endotoxin and kills gram-negative bacteria J Infect Dis 175 1997 621
44. P.M. Flynn J.L. Shenep D.C. Stokes Polymyxin B moderates acidosis and hypotension in established, experimental gram-negative septicemia J Infect Dis 156 1987 706
45. B.D. Freeman I. Yatsiv C. Natanson Continuous arteriovenous hemofiltration does not improve survival in a canine model of septic shock J Am Coll Surg 180 1995 286
46. M.A. Freudenberg T.C. Bog-Hansen U. Back Interaction of lipopolysaccharides with plasma high-density lipoprotein in rats Infect Immun 28 1980 373
47. M.A. Freudenberg U. Meier-Dieter T. Staehelin Analysis of LPS released from Salmonella abortus equi in human serum Microb Pathog 10 1992 93
48. T. Ganz J. Weiss Antimicrobial peptides of phagocytes and epithelia Semin Hematol 34 1997 343
49. C. Garcia R. Saladino C. Thompson Effect of a recombinant endotoxin-neutralizing protein on endotoxin shock in rabbits Crit Care Med 22 1994 1211
50. H. Gazzano-Santoro J.B. Parent L. Grinna High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide Infect Immun 60 1992 4754
51. Y. Ge R.M. Ezzell B.D. Clark Relationship of tissue and cellular interleukin-1 and lipopolysaccharide after endotoxemia and bacteremia J Infect Dis 176 1997 1313
52. Y. Ge R.M. Ezzell R.G. Tompkins Cellular distribution of endotoxin after injection of chemically purified lipopolysaccharide differs from that after injection of live bacteria J Infect Dis 169 1994 95
53. B.P. Giroir P.A. Quint P. Barton Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis Lancet 350 1997 1439
54. D.T. Golenbock J.E. Leggett P. Rasmussen Lipid X protects mice against fatal Escherichia coli infection Infect Immun 56 1988 779
55. D.T. Golenbock J.A. Will C.R. Raetz Lipid X ameliorates pulmonary hypertension and protects sheep from death due to endotoxin Infect Immun 55 1987 2471
56. R.L. Greenman R.M.H. Schein M.A. Martin A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis JAMA 266 1991 1097
57. S.E. Greisman E.J. Young J.B. DuBuy Mechanisms of endotoxin tolerance. VIII. Specificity of serum transfer J Immunol 111 1973 1349
58. G.H. Gudmundsson B. Agerberth J. Odeberg The humane gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes Eur J Biochem 238 1996 325
59. E. Hailman H.S. Lichenstein M.M. Wurfel Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14 J Exp Med 179 1994 269
60. H.W. Harris C. Grunfeld K.R. Feingold Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice J Clin Invest 86 1990 696
61. H.W. Harris C. Grunfeld K.R. Feingold Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death J Clin Invest 91 1993 1028
62. Haziot A. Rong G.-W. V. Bazil Recombinant soluble CD14 inhibits LPS-induced tumor necrosis factor-α production by cells in whole blood J Immunol 152 1994 5868
63. A. Haziot G.W. Rong Lin X.-Y. Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide) J Immunol 154 1995 6529
64. J. Hellman E.M. Zanzot P.M. Loiselle Antiserum against Escherichia coli J5 contains antibodies reactive with outer membrane proteins of heterologous gram-negative bacteria J Infect Dis 176 1997 1260
65. Heumann D. Baumgartner J.-D. H. Jacot-Guillarmod Antibodies to core lipopolysaccharide determinants: Absence of cross-reactivity with heterologous lipopolysaccharides J Infect Dis 163 1991 762
66. D. Heumann P. Gallay S. Betz-Corradin Competition between bactericidal/permeability-increasing protein and lipopolysaccharide-binding protein for lipopolysaccharide binding to monocytes J Infect Dis 167 1993 1351
67. H. Hirasawa T. Sugai Y. Ohtake Blood purification for prevention and treatment of multiple organ failure World J Surg 20 1996 482
68. M. Hirata Y. Shimomura M. Yoshida Characterization of a rabbit cationic protein (CAP18) with lipopolysaccharide-inhibitory activity Infect Immun 62 1994 1421
69. A. Hoess S. Watson G.R. Siber Crystal structure of an endotoxin-neutralizing protein from the horseshoe crab, Limulus anti-LPS factor, at 1.5 AÅ resolution EMBO J 12 1993 3351
70. A.P. Hubsch A.T. Casas J.E. Doran Protective effects of reconstituted high-density lipoprotein in rabbit gram-negative bacteremia models J Lab Clin Med 126 1995 548
71. B.L. Jaber J.G. Pereira Extracorporeal adsorbent-based strategies in sepsis Am J Kidney Dis 30 1997 S44
72. M.A. Johns A. Skehill W.R. McCabe Immunization with rough mutants of Salmonella minnesota . IV. Protection by antisera to O and rough antigens against endotoxin J Infect Dis 147 1983 57
73. S.S. Katz K. Chen S. Chen Potent CD 14-mediated signalling of human leukocytes by Escherichia coli can be mediated by interaction of whole bacteria and host cells without extensive prior release of endotoxin Infect Immun 64 1996 3592
74. T. Kawata J.R. Bristol J.R. Rose Anti-endotoxin activity of a novel synthetic lipid A analog Prog Clin Biol Res 499 1995
75. C.J. Kelly A.C. Cech A.B. Argenteanu Role of bactericidal permeability-increasing protein in the treatment of gram-negative pneumonia Surgery 114 1993 140
76. K.S. Kim J.H. Kang A.S. Cross Functional activities of monoclonal antibodies to the O side chain of Escherichia coli lipopolysaccharides in vitro and in vivo J Infect Dis 157 1988 47
77. T.N. Kirkland E.J. Ziegler An immunoprotective monoclonal antibody to lipoplysaccharide J Immunol 132 1984 2590
78. R.L. Kitchens R.S. Munford Enzymatically deacylated lipopolysaccharide (LPS) can antagonize LPS at multiple sites in the LPS recognition pathway J Biol Chem 270 1995 9904
79. R.L. Kitchens R.S. Munford CD14-dependent internalization of bacterial lipopolysaccharide (LPS) is strongly influenced by LPS aggregation but not by cellular responses to LPS J Immunol 160 1998 1920
80. M. Kloczewiak K.M. Black P. Loiselle Synthetic peptides that mimic the binding site of horseshoe crab anti-lipopolysaccharide factor J Infect Dis 170 1994 1490
81. M. Kodama K. Hanasawa T. Tani New therapeutic method against septic shock—removal of endotoxin using extracorporeal circulation Adv Exp Med Biol 256 1990 653
82. N. Lamping R. Dettmer N.W.J. Schroder LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria J Clin Invest 101 1998 2065
83. R. Landmann H.P. Knopf S. Link Human monocyte CD14 is upregulated by lipopolysaccharide Infect Immun 64 1996 1762
84. R. Landmann W. Zimmerli S. Sansano Increased circulating soluble CD14 is associated with high mortality in gram-negative septic shock J Infect Dis 171 1995 639
85. J.W. Larrick M. Hirata R.F. Balint Human CAP18: A novel antimicrobial lipopolysaccharide-binding protein Infect Immun 63 1995 1291
86. J.W. Larrick M. Hirata H. Zheng A novel granulocyte-derived peptide with lipopolysaccharide-neutralizing activity J Immunol 152 1994 231
87. D.J. Leturcq A.M. Moriarty G. Talbott Antibodies against CD14 protect primates from endotoxin-induced shock J Clin Invest 98 1996 1533
88. D.M. Levine T.S. Parker T.M. Donnelly In vivo protection against endotoxin by plasma high density lipoprotein Proc Natl Acad Sci U S A 90 1993 12040
89. O. Levy C.E. Ooi P. Elsbach Antibacterial proteins of granulocytes differ in interaction with endotoxin: Comparison of bactericidal/permeability-increasing protein, p15s, and defensins J Immunol 154 1995 5403
90. A.A. Lindberg S.E. Greisman S.B. Svenson Induction of endotoxin tolerance with nonpyrogenic O-antigenic oligosacchaide-protein conjugates Infect Immun 41 1983 888
91. J.M. Lonergan J.P. Orlowski T. Sato Extracorporeal endotoxin removal in a canine model of septic shock ASAIO J 40 1994 M654
92. W.A. Lynn D.T. Golenbock Lipopolysaccharide antagonists Immunol Today 13 1992 271
93. W.A. Lynn Y. Liu D.T. Golenbock Neither CD14 nor serum is absolutely necessary for activation of mononuclear phagocytes by bacterial lipopolysaccharide Infect Immun 61 1993 4452
94. M.N. Marra M.B. Thornton J.L. Snable Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5 Crit Care Med 22 1994 559
95. W.R. McCabe Immunization with R mutants of S. minnesota . I. Protection against challenge with heterologous gram-negative bacilli J Immunol 108 1972 601
96. W.R. McCabe S.C. Bruins D.E. Craven Cross-reactive antigens: Their potential for immunization-induced immunity to gram-negative bacteria J Infect Dis 136 1977 S161
97. W.R. McCabe A. DeMaria H. Berberich Immunization with rough mutants of Salmonella minnesota : Protective activity of IgM and IgG antibody to the R595 (Re chemotype) mutant J Infect Dis 158 1988 291
98. W.R. McCabe B.E. Kreger M. Johns Type-specific and cross-reactive antibodies in gram-negative bacteremia N Engl J Med 287 1972 261
99. R.V. McCloskey R.C. Straube C. Sanders Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial Ann Intern Med 121 1994 1
100. J.A. Montaraz A.J. Winter D.M. Hunter Protection against Brucella abortus in mice with O-polysaccharide specific monoclonal antibodies Infect Immun 51 1986 961
101. T. Morita S. Ohtsubo T. Nakamura Isolation and biological activities of limulus anticoagulant (anti-LPS factor) which interacts with lipopolysaccharide (LPS) J Biochem 97 1985 1611
102. D.C. Morrison D.M. Jacobs Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides Immunochemistry 13 1976 813
103. R.S. Munford C.L. Hall J.M. Dietschy Binding of Salmonella typhimurium lipopolysaccharides to rat high-density lipoproteins Infect Immun 34 1981 835
104. R.S. Munford C.L. Hall J.M. Lipton Biological activity, lipoprotein-binding behavior, and in vivo disposition of extracted and native forms of Salmonella typhimurium lipopolysaccharides J Clin Invest 70 1982 877
105. T. Muta T. Miyata F. Tokunaga Primary structure of anti-lipopolysaccharide factor from American horseshoe crab, Limulus polyphemus J Biochem 101 1987 1321
106. D. Nelson N. Kuppermann G.R. Fleisher Recombinant endotoxin neutralizing protein improves survival from Escherichia coli sepsis in rats Crit Care Med 23 1995 92
107. 106–138-IgG, in whole blood Infect Immun 65 1997 2160
108. C.E. Ooi J. Weiss M.E. Doerfler Endotoxin-neutralizing properties of the 25 kD N-terminal fragment and a newly isolated 30 kD C-terminal fragment of the 55–60 kD bactericidal/permeability-increasing protein of human neutrophils J Exp Med 174 1991 649
109. 2-terminal fragment carries all the antibacterial activities of the human neutrophil 60 kDa bactericidal/permeability-increasing protein J Biol Chem 262 1987 14891
110. S.M. Opal J.E. Palardy M.N. Marra Relative concentrations of endotoxin-binding proteins in body fluids during infection Lancet 344 1994 429
111. D. Pajkrt J.E. Doran F. Koster Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia J Exp Med 184 1996 1601
112. C.T. Park S.D. Wright Plasma lipopolysaccharide-binding protein is found associated with a particle containing apolipoprotein A-I, phospholipid, and factor H-related proteins J Biol Chem 271 1996 18054
113. T.S. Parker D.M. Levine J.C.C. Chang Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood Infect Immun 63 1995 253
114. Z.M. Quezado C. Natanson S.M. Banks Therapeutic trial of reconstituted human high-density lipoprotein in a canine model of gram-negative septic shock J Pharmacol Exp Ther 272 1995 604
115. Z.M.N. Quezado C. Natanson D.W. Alling A controlled trial of HA-1A in a canine model of gram-negative septic shock JAMA 269 1993 2221
116. T.E. Read C. Grunfeld Z.L. Kumwenda Triglyceride-rich lipoproteins prevent septic death in rats J Exp Med 182 1995 267
117. T.E. Read H.W. Harris C. Grunfeld Chylomicrons enhance endotoxin excretion in bile Infect Immun 61 1993 3496
118. D. Rifkind Prevention by polymyxin B of endotoxin lethality in mice J Bacteriol 93 1967 1463
119. M.A. Rogy L.L. Moldawer H.S.A. Oldenburg Anti-endotoxin therapy in primate bacteremia with HA-1A and BPI Ann Surg 220 1994 77
120. M.A. Rogy H.S.A. Oldenburg S.E. Calvano The role of bactericidal/permeability-increasing protein in the treatment of primate bacteremia and septic shock J Clin Immunol 14 1994 120
121. R.I. Roth D. Su A.H. Child Limulus antilipopolysaccharide factor prevents mortality late in the course of endotoxemia J Infect Dis 177 1998 388
122. R. Saladino C. Garcia C. Thompson Efficacy of a recombinant endotoxin neutralizing protein in rabbits with Escherichia coli sepsis Circ Shock 42 1994 104
123. C.A. Salkowski G. Detore A. Franks Pulmonary and hepatic gene expression following cecal ligation and puncture: Monophosphoryl lipid A prophylaxis attenuates sepsis-induced cytokine and chemokine expression and neutrophil infiltration Infect Immun 66 1998 3569
124. K. Sato Y.C. Yoo A. Fukushima A novel synthetic lipid A analog with low endotoxicity, DT-5461, prevents lethal endotoxemia Infect Immun 63 1995 2859
125. T. Sato J.P. Orlowski M. Zborowskis Experimental study of extracorporeal perfusion for septic shock ASAIO J 39 1993 M790
126. D.E. Schiff C.A. Wass Cryz S.J. Jr Estimation of protective levels of anti-O-specific lipopolysaccharide immunoglobulin G antibody against experimental Escherichia coli infection Infect Immun 61 1993 975
127. R.R. Schumann S.R. Leong G.W. Flaggs Structure and function of lipopolysaccharide-binding protein Science 249 1990 1429
128. G.R. Siber D. Nelson N. Kupperman Recombinant endotoxin neutralizing protein from L. polyphemus reduces mortality of gram-negative sepsis in rat models [abstract] J Cell Biochem 16C 1992 173(CB414)
129. A.M. Stack R.A. Saladino G.R. Siber A comparison of bactericidal/permeabilityincreasing protein variant versus recombinant endotoxin-neutralizing protein for the treatment of Escherichia coli sepsis in rats Crit Care Med 25 1997 101
130. W.J. Tate H.L. Douglas A.I. Braude Protection against lethality of E. coli endotoxins with “O” antiserum Ann N Y Acad Sci 133 1966 746
131. P.S. Tobias J.C. Mathison R.J. Ulevitch A family of lipopolysaccharide binding proteins involved in responses to gram-negative sepsis J Biol Chem 263 1988 13479
132. P.S. Tobias K.P.W.J. McAdam K. Soldau Control of lipopolysaccharide-high-density lipoprotein interactions by an acute-phase reactant in human serum Infect Immun 50 1985 73
133. P.S. Tobias J. Soldau R.J. Ulevitch Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum J Exp Med 164 1986 777
134. P.S. Tobias K. Soldau J.A. Gegner Lipopolysaccharide binding protein-mediated complexation of lipopolysaccharide with soluble CD14 J Biol Chem 270 1995 10482
135. P.S. Tobias K. Soldau N.M. Iovine Lipopolysaccharide (LPS)-binding proteins BPI and LBP form different types of complexes with LPS J Biol Chem 272 1997 18682
136. P.S. Tobias R.J. Ulevitch Control of lipopolysaccharide high-density lipoprotein binding by acute-phase protein(s) J Immunol 131 1983 1913
137. R.J. Ulevitch A.R. Johnston The modification of biophysical and endotoxin properties of bacterial lipopolysaccharides by serum J Clin Invest 62 1978 1313
138. R.J. Ulevitch A.R. Johnston D.B. Weinstein New function of high density lipoproteins. Their participation in intravascular reactions of bacterial lipopolysaccharides J Clin Invest 64 1979 1516
139. R.J. Ulevitch A.R. Johnston D.B. Weinstein New function for high density lipoproteins. Isolation and characterization of a bacterial lipopolysaccharide-high density lipoprotein complex formed in rabbit plasma J Clin Invest 67 1981 827
140. van der Poll T. C.C. Braxton S.M. Coyle Effect of hypertriglyceridemia on endotoxin responsiveness in humans Infect Immun 63 1995 3396
141. van Lenten B.J. A.M. Fogelman M.E. Haberland The role of lipoproteins and receptor-mediated endocytosis in the transport of bacterial lipopolysaccharide Proc Natl Acad Sci U S A 83 1986 2704
142. T.J. Vandermeer M.J. Menconi J. Zhuang Protective effects of a novel 32-amino acid C-terminal fragment of CAP18 in endotoxemic pigs Surgery 117 1995 656
143. von der Mohlen M.A.M. A.N. Kimmings N.I. Wedel Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein J Infect Dis 172 1995 144
144. H.S. Warren S.F. Amato C. Fitting Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide J Exp Med 177 1993 89
145. H.S. Warren M.L. Glennon N. Wainwright Binding and neutralization of endotoxin by Limulus antilipopolysaccharide factor Infect Immun 60 1992 2506
146. H.S. Warren S. Kania G.R. Siber Binding and neutralization of bacterial lipopolysaccharide by colistin nonapeptide Antimicrob Agents Chemother 28 1985 107
147. Weersink A.J.L. Van Kessel K.P.M. Van den Tol M.E. Human granulocytes express a 55-kDa lipopolysaccharide-binding protein on the cell surface that is identical to the bactericidal/permeability-increasing protein J Immunol 150 1993 253
148. 2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria J Clin Invest 90 1992 1122
149. J. Weiss P. Eslbach I. Olsson Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes J Biol Chem 253 1978 2664
150. J. Weiss K. Muello M. Victor The role of lipopolysaccharides in the action of the bactericidal/permeability-increasing neutrophil protein on the bacterial envelope J Immunol 132 1984 3109
151. C.G. Wilde J.J. Seilhamer M. McGrogan Bactericidal/permeability-increasing protein and lipopolysaccharide (LPS)-binding protein. LPS binding properties and effects on LPS-mediated cell activation J Biol Chem 269 1994 17411
152. S.D. Wright R.A. Ramos P.S. Tobias CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein Science 249 1990 1431
153. M.M. Wurfel E. Hailman S.D. Wright Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein J Exp Med 181 1995 1743
154. M.M. Wurfel S.T. Kunitake H. Lichenstein Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS J Exp Med 180 1994 1025
155. M. Zanetti R. Gennaro D. Romeo Cathelicidins: A novel protein family with a common proregion and a variable C terminal antimicrobial domain FEBS Lett 374 1995 1
156. Ziegler E.J. Fisher C.J. Jr C.L. Sprung Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: A randomized, double-blind, placebo-controlled trial N Engl J Med 324 1991 429
157. E.J. Ziegler J.A. McCutchan H. Douglas Prevention of lethal Pseudomonas bacteremia with epimerase-deficient E. coli antiserum Transactions of the Association of American Physicians 88 1975 101
158. E.J. Ziegler J.A. McCutchan J. Fierer Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli N Engl J Med 307 1982 1225